Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease

Nephrology Dialysis Transplantation

Volumn 27, Issue 11, 2012, Pages 4131-4137

  Boertien, Wendy E ^a   Meijer, Esther ^a   Zittema, Debbie ^a   Van Dijk, Marjan A ^b   Rabelink, Ton J ^b   Breuning, Martijn H ^b   Struck, Joachim ^c   Bakker, Stephan J L ^a   Peters, Dorien J M ^b   De Jong, Paul E ^a   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

ADPKD; copeptin; GFR; vasopressin

Indexed keywords

ATENOLOL; COPEPTIN; ENALAPRIL; INULIN; PLACEBO; VASOPRESSIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; INULIN CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; MODIFICATION OF DIET IN RENAL DISEASE EQUATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; SEX DIFFERENCE;

ADULT; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; VASOPRESSINS;

EID: 84869428027     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs070     Document Type: Article

References (32)

1. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329:332-342. (Pubitemid 23210687)
2. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287-1301. (Pubitemid 46552051)
3. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardio-vasc Res 2001; 51:372-390. (Pubitemid 32718586)
4. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11:406-410.
5. Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 2003; 64:1157-1162. (Pubitemid 37153779)
6. Belibi FA, Reif G, Wallace DP et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66:964-973. (Pubitemid 39120999)
7. Meijer E, Gansevoort RT, de Jong PE et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant 2011; 26:2445-2453.
8. Wang X, Gattone V, Harris PC et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16:846-851. (Pubitemid 41710293)
9. Torres VE, Wang X, Qian Q et al. Effective treatment of an ortholo-gous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10:363-364. (Pubitemid 38508512)
10. Gattone VH, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9:1323-1326. (Pubitemid 37279858)
11. Nagao S, Nishii K, Katsuyama M et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006; 17:2220-2227. (Pubitemid 44141912)
12. Preibisz JJ, Sealey JE, Laragh JH et al. Plasma and platelet vaso-pressin in essential hypertension and congestive heart failure. Hypertension 1983; 5: I129-I138
13. Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 1976; 57:1109-1116.
14. Robertson GL, Mahr EA, Athar S et al. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973; 52:2340-2352.
15. Morgenthaler NG, Struck J, Alonso C et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of va-sopressin. Clin Chem 2006; 52:112-119. (Pubitemid 43032474)
16. Morgenthaler NG, Struck J, Jochberger S et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19:43-49. (Pubitemid 351317895)
17. Szinnai G, Morgenthaler NG, Berneis K et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007; 92:3973-3978. (Pubitemid 47607649)
18. Meijer E, Bakker SJ, Van der Jagt EJ et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6:361-368.
19. Van Dijk MA, Breuning MH, Duiser R et al. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2003; 18:2314-2320. (Pubitemid 37336819)
20. Ravine D, Gibson RN, Walker RG et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343:824-827. (Pubitemid 24147512)
21. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26:2500-2504. (Pubitemid 41676723)
22. Fenske W, Stork S, Blechschmidt A et al. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009; 94:123-129.
23. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317:1098
24. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
25. Meijer E, Bakker SJ, Halbesma N et al. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010; 77:29-36.
26. Meijer E, Bakker SJ, de Jong PE et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009; 88:561-567.
27. Zittema D, Boertien WE, Van Beek AP et al. Plasma arginine vaso-pressin and copeptin levels in relation to renal concentrating capacity in early stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Neph (in press; doi:10.2215/CJN.11311111)
28. Torres VE, Meijer E, Bae KT et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis 2011; 57:692-699.
29. Barua M, Cil O, Paterson AD et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009; 20:1833-1838.
30. Torres VE, King BF, Chapman AB et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2:112-120.
31. Fick-Brosnahan GM, Belz MM, McFann KK et al. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002; 39:1127-1134. (Pubitemid 34591926)
32. Wong H, Vivian L, Weiler G et al. Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis 2004; 43:624-628. (Pubitemid 38401877)